(Q80427546)

English

Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?

scientific article published on 09 February 2007

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17548440

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17548440%20AND%20SRC:MED&resulttype=core&format=json

retrieved

31 December 2019

title

Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis? (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17548440

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17548440%20AND%20SRC:MED&resulttype=core&format=json

retrieved

31 December 2019

author

Per Soelberg Sørensen

series ordinal

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17548440

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17548440%20AND%20SRC:MED&resulttype=core&format=json

retrieved

31 December 2019

author name string

Koch-Henriksen N

series ordinal

2

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17548440

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17548440%20AND%20SRC:MED&resulttype=core&format=json

retrieved

31 December 2019

Bendtzen K

series ordinal

3

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17548440

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17548440%20AND%20SRC:MED&resulttype=core&format=json

retrieved

31 December 2019

publication date

9 February 2007

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17548440

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17548440%20AND%20SRC:MED&resulttype=core&format=json

retrieved

31 December 2019

published in

Multiple Sclerosis Journal

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17548440

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17548440%20AND%20SRC:MED&resulttype=core&format=json

retrieved

31 December 2019

volume

13

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17548440

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17548440%20AND%20SRC:MED&resulttype=core&format=json

retrieved

31 December 2019

issue

5

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17548440

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17548440%20AND%20SRC:MED&resulttype=core&format=json

retrieved

31 December 2019

page(s)

616-621

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17548440

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17548440%20AND%20SRC:MED&resulttype=core&format=json

retrieved

31 December 2019

Identifiers

DOI

10.1177/1352458506072344

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17548440

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17548440%20AND%20SRC:MED&resulttype=core&format=json

retrieved

31 December 2019

PubMed publication ID

17548440

1 reference

stated in

Europe PubMed Central

PubMed publication ID

17548440

reference URL

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17548440%20AND%20SRC:MED&resulttype=core&format=json

(Q80427546)

Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)